The pattern of mutations in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) strains that confer resistance to didanosine (ddI) was analyzed in 2 groups of patients receiving either ddI monotherapy or ddI plus hydroxyurea (HU) combination therapy. Twelve patients receiving combination therapy and 8 receiving monotherapy were tested. Combinations of ddI plus HU did not prevent the onset of mutations, which emerged in 50% of the patients in this group compared with 25% of the ddI monotherapy group. In addition, in 1 patient from the combination therapy arm, who had a limited response to the therapy, an unusual pattern of mutations was found: the insertion of 2 amino acids between residues 69 and 70, a region critical for resistance to nucleoside analogs. The higher efficacy of the combination of HU and ddI compared with that of ddI monotherapy cannot be attributed to a delayed or decreased onset of resistance to ddI.
Drug-resistant mutants of human immunodeficiency virus
24 weeks of treatment, the genotypic changes in the HIV-1 RT gene associated with ddI resistance in ddI-treated patients who type 1 (HIV-1) emerge under the selective pressure of prolonged chemotherapy. There are specific mutations in the HIVdid or did not receive HU. 1 reverse transcriptase (RT) gene that confer resistance to the nucleoside analogues, such as zidovudine, didanosine (ddI), Methods zalcitabine (ddC), and lamivudine [1] . Mutation at codons 41, 67, 70, 215, and 219 of HIV-1 RT confer resistance to zidovuPatients. Twenty patients were selected from a larger group dine [1, 2] . HIV-1 strains with mutations at codons, 62, 75, of 58 who were in an ongoing clinical trial. To be eligible, each 77, 116, and 151 have been reported in patients receiving patient needed documentation of HIV-1 infection by ELISA conzidovudine and ddI combination therapy; these mutations confirmed by Western blot. Upon entry, each patient was required to fer on the virus a reduced sensitivity to multiple antiretroviral have 250-500 CD4 cells/mL determined one time within 2 weeks before enrollment. Patients were randomly assigned to each group; dideoxynucleosides, and 151 is a critical mutation in the develrandomization was done by use of a computer-generated two-digit opment of multidrug resistance [3, 4] . Although mutation at numeric list. On the basis of the second digit, patients were enrolled codon 74 is considered to be the primary mutation responsible into a particular study arm.
for ddI resistance [5 -7] , other mutations have been reported Blood samples were obtained prior to therapy and again after that decrease the susceptibility of HIV-1 to ddI. These muta-24 weeks of therapy from 20 patients treated with either the combitions are located at codons 65 and 184 [8, 9] . nation of ddI plus HU or ddI monotherapy. Twelve of these patients Combinations of drugs have been used to limit negative were treated with ddI plus HU (group I), and 8 were treated with effects due to the emergence of mutations. Interest has grown ddI monotherapy (group II). Eight patients enrolled in group I and in the use of hydroxyurea ( HU ) and ddI as anti -HIV-1 therapy 5 enrolled in group II had received zidovudine therapy for ú1 [10 -18] . We have been studying the in vitro and in vivo effects year prior to our study, but they stopped this therapy at least 60 of ddI plus HU therapy [10, 11, 14, 19] . We compared, after days before the beginning of this clinical trial.
Patients treated with ddI monotherapy received ddI at the following concentrations twice daily, according to weight: Patients weighing õ50 kg were given 200 mg; those weighing 50-75 kg were given 400 mg; and those weighing ú75 kg were given 600 viously recognized to confer resistance to ddI (codons 65, 74,
If the PCR products were not visible on an agarose gel using and 184) [5, 8, 9] . confer resistance to zidovudine [2] . Six of them were enrolled a T69S mutation appeared, together with an insertion of 2 that the finger subdomain of p66 could be involved in the appropriate positioning and conformation of the template strand amino acids (Ser-Ser) between residues 69 and 70. After 24 weeks, a further change was observed: The second serine (of that could influence the polymerase active site. Therefore, mutations in that region could indirectly influence the ability of the insertion) changed to glycine, resulting in a Ser-Gly insertion (figure 2B). We can exclude the possibility that this was the active site to accept or reject the incoming nucleotides [28] .
The majority of the mutations we found were concentrated in due to contamination because several RT-PCR reactions were done at different times, starting from independent RNA prepathis region. Of interest, patient 6 had HIV-1 mutants with an insertion of 2 polar amino acids (Ser-Ser) in this critical region, rations. The sequence data of the RT-PCR products on both strands were consistent.
after only 12 weeks of therapy. That insertion was still present after 24 weeks of therapy; however, the second serine mutated Discussion into glycine (Ser-Gly) ( figure 2B ). An additional T69S mutation appeared in the viral RT of this patient at week 12. Thus, RT is made of two subunits, p66 (560 amino acids) and p51 at week 12 there was a new sequence in this region (AGTAGT-(440 amino acids). In the polymerase domain, there are four AGTAGT) characterized by the repetition of four serines subdomains, called fingers, palm, thumb, and connection. The (SSSS), and at week 24 this sequence changed to AGTAGTpolymerase active site is located in the palm subdomain of AGTGGT, which translates to amino acids SSSG. p66. It is known that nucleoside analogues bind to a hydrophoAlthough this patient responded to the combination of HU bic pocket close to the active site in the p66 subdomain [27] .
plus ddI, his response was the least successful. This confirms Most of the mutations that confer resistance to the nucleoside that the region between 65 and 74 is critically associated with inhibitors do not lie in the immediate vicinity of the polymerase changes in the sequence of HIV-1 RT after treatment with ddI. active site but are located within both the finger and palm
Ten of 12 patients in the combination therapy arm and 6 of subdomains, in a region that interacts with the template primer (the region spanning residues 65 -74) [28, 29] . It was suggested 8 in the monotherapy arm were also screened for the presence / 9d35$$oc15 08-14-97 14:12:59 jinfa UC: J Infect of the 151 RT mutation conferring multidrug resistance [3, 4] , in both groups: 50% in group I and 25% in group II. HIV-1 mutants resistant to ddI have been rendered sensitive to this but this mutation was not found (data not shown).
Consistent with similar documented observations [30] , the drug by the addition of HU [32] (Lori F et al., unpublished data). Therefore, we suggest that the onset of mutations is not onset of mutations at position 74 selected for ddI or ddI plus HU treatment was not significantly affected by zidovudine prehampered, but the replication of resistant mutants is inhibited more efficiently in the presence of HU. treatment. It has, however, been reported [7, 31] that both alternating and simultaneous combinations of zidovudine and Potentiation of HU plus ddI therapy might be achieved by the addition of a third HIV-1 inhibitor. This may suppress the ddI delayed the onset of mutation 74. The combination of HU and ddI, to the contrary, did not delay the onset of this mutation.
virus almost completely and prevent the onset of resistance. However, the combination of HU plus ddI represents a solid Mutation 74 appeared in the combination therapy arm more frequently (50%) than in the monotherapy arm (12.5%) (figure basis for the initial treatment of HIV-1 infection. 1). However, viremia levels after 24 weeks were lower in the group of patients receiving the HU plus ddI combination ther-
